Changing patterns in the use of slow acting antirheumatic drugs for the treatment of rheumatoid arthritis

New Zealand Medical Journal

Volumn 111, Issue 1067, 1998, Pages 200-203

  Horsfall, Melissa W J ^a   Shaw, John P ^b   Highton, John ^c   Cranch, Phillip J ^b  

^a UNIVERSITY OF OTAGO   (New Zealand)

^b UNIVERSITY OF OTAGO   (New Zealand)

^c UNIVERSITY OF OTAGO   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRHEUMATIC AGENT; AURANOFIN; AZATHIOPRINE; GOLD; HYDROXYCHLOROQUINE; METHOTREXATE; PENICILLAMINE; SALAZOSULFAPYRIDINE;

ADULT; AGED; ARTICLE; BONE MARROW SUPPRESSION; COMBINATION CHEMOTHERAPY; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG UTILIZATION; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PNEUMONIA; PRESCRIPTION; REMISSION; RHEUMATOID ARTHRITIS; TREATMENT PLANNING;

ADULT; AGED; AMBULATORY CARE; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; AURANOFIN; COHORT STUDIES; DELAYED-ACTION PREPARATIONS; DRUG UTILIZATION; FEMALE; HUMANS; MALE; METHOTREXATE; MIDDLE AGED; NEW ZEALAND; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 0032511162     PISSN: 00288446     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. Wilske K, Healey L. Remodeling the pyramid: a concept whose time has come. J Rheumatol 1989; 16: 565-7.
2. Brook A, Corbett, M. Radiographic changes in early rheumatoid disease. Ann Rheum Dis 1977; 36: 71-3.
3. Palmer DG. The management of rheumatoid arthritis of recent onset. NZ Med J 1992; 105: 293-4.
4. van de Putte L, van Riel P. Do disease-modifying antirheumatic drugs actually modify disease course in rheumatoid arthritis? Clin Immunother 1994; 1: 319-22
5. Suarez-Almazor M, Soskolne C, Saunders L, Russell A. Use of second line drugs for the treatment of rheumatoid arthritis in Edmonton, Alberta. Patterns of prescription and longterm effectiveness. J Rheumatol 1995; 22: 836-43.
6. Egsmose C, Lund B, Borg G et al. Patients with rheumatoid arthritis benefit from early 2nd line therapy: 5 year followup of a prospective double blind placebo controlled study. J Rheumatol 1995; 22: 2208-13.
7. Emery P. Early rheumatoid arthritis: therapeutic strategies. Scand J Rheumatol 1994; 23: Suppl 100: 3-7.
8. Sambrook PN. Systemic corticosteroids in arthritis. New Ethicals 1993; June: 17-21.
9. Fries J. Reevaluating the therapeutic approach to rheumatoid arthritis: the "Sawtooth" strategy. J Rheumatol 1990; 17 Suppl 22: 12-5.
10. Fries J, Williams C, Ramey D, Bloch D. The relative toxicity of alternative therapies for rheumatoid arthritis: implications for the therapeutic progression. Semin Arthritis Rheum 1993; 23: 68-73.
11. Epstein W. Efficacy of standard slow-acting antirheumatic drugs. Semin Arthritis Rheum 1994; 23 (6 Suppl 2): 32-8.
12. Cranch PJ. Slow-acting antirheumatic drugs (SAARDS) in a sample population of rheumatology out-patients. Dunedin: MPharm Thesis, University of Otago; 1990.
13. Arnett F, Edworthy S, Bloch D et al. Revised criteria for the classification of rheumatoid arthritis. Arthritis Rheumatism 1988; 31: 315-24.
14. Chambers J, Cleveland W, Kleiner B, Tukey P. Graphical methods for data analysis. Belmont: Wadsworth International; 1983.
15. Schnabel A, Gross W. Low-dose methotrexate in rheumatic diseases efficacy, side effects, and risk factors for side effects. Semin Arthritis Rheum 1994; 23: 310-27.
16. Salaffi F, Carotti M, Sartini A, Cervini C. A prospective study of the long-term efficacy and toxicity of low-dose methotrexate in rheumatoid arthritis. Clin Exp Rheumatol 1995; 13: 23-8.
17. Weinblatt MW, Weissman B, Holdsworth D et al. Long term prospective study of methotrexate in the treatment of rheumatoid arthritis. Arthritis Rheum 1992; 35: 129-37.
18. Morand E, McCloud P, Littlejohn G. Life table analysis of 879 treatment episodes with slow acting antirheumatic drugs in community rheumatology practice. J Rheumatol 1992; 19: 704-8.
19. Wolfe F, Hawley D, Cathey, M. Termination of slow acting antirheumatic therapy in rheumatoid arthritis: a 14-year prospective evaluation of 1017 consecutive starts. J Rheumatol 1990; 17: 994-1002.
20. Alarcon G, Tracy I, Blackburn W. Methotrexate in rheumatoid arthritis. Toxic effects as the major factor in limiting long-term treatment. Arthritis Rheum 1989; 32: 671-6.
21. Wijnands M, Van't Hof M, Van Leeuwen M et al. Long-Term second-line treatment: a prosective drug survival study. Br J Rheumatol 1992; 31: 253-8.
22. Felson D, Anderson J, Meenan R. The comparative efficacy and toxicity of second-line drugs in rheumatoid arthritis. Arthritis Rheum 1990; 33: 1449-61.
23. Felson D, Anderson J, Meenan, R. Use of short-term efficacy/toxicity tradeoffs to select second-line drugs in rheumatoid arthritis. Arthritis Rheum 1992; 35: 1117-25.
24. Alarcon C, Lopez-Mendez A, Walter J et al. Radiographic evidence of disease progression in methotrexate treated and nonmethotrexate disease modifying antirheumatic drug treated rheumatoid arthritis patients. J Rheumatol 1992; 19: 868-73.
25. Fries J, Williams C, Ramey D, Bloch D. The relative toxicity of disease-modifying antirheumatic drugs. Arthritis Rheum 1993; 36: 297-306.